MGO One Seven LLC Has $1.13 Million Stock Holdings in Sanofi (NASDAQ:SNY)

MGO One Seven LLC increased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 125.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,408 shares of the company's stock after buying an additional 13,022 shares during the quarter. MGO One Seven LLC's holdings in Sanofi were worth $1,129,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SNY. Synergy Asset Management LLC acquired a new position in shares of Sanofi during the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. lifted its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in shares of Sanofi during the fourth quarter worth about $31,000. Finally, Sierra Ocean LLC acquired a new stake in shares of Sanofi in the 4th quarter worth about $44,000. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Down 2.3 %

Shares of NASDAQ:SNY opened at $52.32 on Friday. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a market capitalization of $132.17 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The business has a fifty day moving average price of $54.53 and a two-hundred day moving average price of $52.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a $2.0369 dividend. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio is presently 57.14%.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of analyst reports. BNP Paribas initiated coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.